TY  - JOUR
AU  - Grau, Santiago
AU  - Miró, Jose Maria
AU  - Olalla, Julian
AU  - Alcalá, Juan C
AU  - Castro, Antonio
AU  - Rubio-Rodríguez, Dario
AU  - Rubio-Terrés, Carlos
PY  - 2022
DO  - 10.1080/14787210.2023.2149490
UR  - http://hdl.handle.net/10668/19684
T2  - Expert review of anti-infective therapy
AB  - Current recommended antiretroviral regimens include a combination of two (dual; DT) or three (triple; TT) antiretroviral drugs. This study aims to determine whether the quality of evidence from clinical trials of dolutegravir (dolutegravir/lamivudine...
LA  - en
KW  - HIV
KW  - bictegravir
KW  - clinical trial
KW  - dolutegravir
KW  - emtricitabine
KW  - lamivudine drug combination
KW  - review
KW  - rilpivirine drug combination
KW  - tenofovir alafenamide drug combination
KW  - Humans
KW  - HIV Infections
KW  - Anti-HIV Agents
KW  - Emtricitabine
KW  - Adenine
KW  - Heterocyclic Compounds, 3-Ring
KW  - Heterocyclic Compounds, 4 or More Rings
TI  - Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
TY  - research article
VL  - 21
ER  -